✦ LIBER ✦

Re-evaluation of immunological parameters in immunotherapy for advanced carcinoma of the digestive tract

✍ Scribed by Hanaue, Hitoshi ;Yoshizaki, Satoshi ;Kurosawa, Tsutomu

Book ID: 110680198
Publisher: Springer-Verlag
Year: 1983
Tongue: English
Weight: 435 KB
Volume: 18
Category: Article
ISSN: 0435-1339
DOI: 10.1007/bf02774956

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acth and cortisone in advanced carcinoma

Acth and cortisone in advanced carcinoma of the digestive tract

✍ R. W. Postlethwait; Vince Moseley; Kelly T. McKee; John H. Murdoch Jr.; William 📂 Article 📅 1951 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB 👁 2 views

Immunological evaluation of personalized

Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients

✍ Yuji Sato; Toshiyoshi Fujiwara; Takashi Mine; Hiroki Shomura; Shigenori Homma; Y 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB

A combination of gemcitabine and 5-fluor

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

✍ Cascinu, S; Silva, R R; Barni, S; Labianca, R; Frontini, L; Piazza, E; Pancera, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 73 KB

Intensive weekly chemotherapy is not eff

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

✍ Cascinu, S; Frontini, L; Comella, G; Barni, S; Labianca, R; Battelli, N; Casaret 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 62 KB

Risk factors for multicentric occurrence

Risk factors for multicentric occurrence of carcinoma in the upper aerodigestive tract—analysis with a serial histologic evaluation of the whole resected-esophagus including carcinoma

✍ Masaru Morita; Koshi Araki; Hiroshi Saeki; Yoshihisa Sakaguchi; Hideo Baba; Keiz 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Ifosfamide, paclitaxel, and cisplatin fo

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract : Final report of a Phase II trial evaluating two dosing schedules

✍ Dean F. Bajorin; John A. McCaffrey; Paul M. Dodd; Susan Hilton; Madhu Mazumdar; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

## BACKGROUND. A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week intervals to assess its feasibility